The FDA has approved a first-of-its-kind treatment for dry age-related macular degeneration (AMD), a leading cause of blindness in adults over 55.

Toll-like receptors (TLRs) are vital components of the immune system, acting as sentinels that detect and respond to ...

Astellas Pharma Inc. (ALPMY, ALPMY) announced that the U.S. Food and Drug Administration accepted the revised supplemental New Drug ...

Since July 2024, faricimab has also been approved in Europe for the treatment of visual impairment due to macular oedema ...

Lenvatinib is under clinical development by AiViva BioPharma and currently in Phase II for Diabetic Macular Edema.

Fresenius, through its operating company Fresenius Kabi, is broadening its growing biopharma portfolio through a new licensing agreement with South Korea’s SamChunDang Pharm. Under the agreement, ...

Pravin U. Dugel, MD, Ocular’s Executive Chairman, President and CEO, will provide an update regarding the enrollment status of SOL-R, the Company’s second registrational trial of AXPAXLI™ for the ...

Shares of Outlook Therapeutics jumped after the company said it continues to progress the development of its treatment for wet age-related macular degeneration, which causes blurred or reduced central ...

Jedd Comiskey, Senior Vice President, Head of Europe, highlights the recent NICE recommendation of LYTENAVA™ (bevacizumab gamma) for the ...

Shares of Outlook Therapeutics jumped after the company said it continues to progress the development of its treatment for wet age-related macular degeneration, which causes blurred or reduced ...